As of 2026-03-09, the Fair Value of Elicera Therapeutics AB (ELIC.ST) is -1.79 SEK. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 6.50 SEK, the upside of Elicera Therapeutics AB is -127.58%.
With the market price of 6.50 SEK and our fair value calculation, Elicera Therapeutics AB (ELIC.ST) is not a good investment. Investing in ELIC.ST stocks now will result in a potential loss of 127.58%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | 5Y Avg | |
| Net income | -13.12 | -19.44 | -16.40 | -16.11 | -17.41 | -16.49 |
| YoY growth | -364.75% | -48.16% | 15.64% | 1.75% | -8.05% | -80.71% |
| Market Cap (mil) | 315.51 |
| P/E | |
| Forward P/E |
| EPS | -0.36 |
| Avg earnings growth rate | -80.71% |
| TTM earnings | -17.41 |